Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein

NCT00048880 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

NIH

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: HeFi-1 Monoclonal Antibody

Sponsor

National Cancer Institute (NCI)